Key clinical point:
Major finding: Idarubicin was associated with a higher risk of grade 3 or 4 hepatotoxicity, and vincristine was associated with a borderline risk.
Study details: Retrospective review of 51 PEG-ASP dosing events in 26 adult patients with ALL.
Disclosures: The study was internally funded. The authors reported having no relevant conflicts of interest.
Source: Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
This Week's Must Reads
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018